2i6a: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Adenosine kinase (AK) is an enzyme responsible for converting endogenous, adenosine (ADO) to adenosine monophosphate (AMP) in an adenosine, triphosphate- (ATP-) dependent manner. The structure of AK consists of two, domains, the first a large alpha/beta Rossmann-like nucleotide binding, domain that forms the ATP binding site, and a smaller mixed alpha/beta, domain, which, in combination with the larger domain, forms the ADO, binding site and the site of phosphoryl transfer. AK inhibitors have been, under investigation as antinociceptive, antiinflammatory, and, anticonvulsant as well as antiinfective agents. In this work, we report, the structures of AK in complex with two classes of inhibitors: the first, ADO-like, and the second, a novel alkynylpyrimidine series. The two, classes of structures, which contain structurally similar substituents, reveal distinct binding modes in which the AK structure accommodates the, inhibitor classes by a 30 degrees rotation of the small domain relative to, the large domain. This change in binding mode stabilizes an open and a, closed intermediate structural state and provide structural insight into, the transition required for catalysis. This results in a significant, rearrangement of both the protein active site and the orientation of the, alkynylpyrimidine ligand when compared to the observed orientation of, nucleosidic inhibitors or substrates.
Adenosine kinase (AK) is an enzyme responsible for converting endogenous adenosine (ADO) to adenosine monophosphate (AMP) in an adenosine triphosphate- (ATP-) dependent manner. The structure of AK consists of two domains, the first a large alpha/beta Rossmann-like nucleotide binding domain that forms the ATP binding site, and a smaller mixed alpha/beta domain, which, in combination with the larger domain, forms the ADO binding site and the site of phosphoryl transfer. AK inhibitors have been under investigation as antinociceptive, antiinflammatory, and anticonvulsant as well as antiinfective agents. In this work, we report the structures of AK in complex with two classes of inhibitors: the first, ADO-like, and the second, a novel alkynylpyrimidine series. The two classes of structures, which contain structurally similar substituents, reveal distinct binding modes in which the AK structure accommodates the inhibitor classes by a 30 degrees rotation of the small domain relative to the large domain. This change in binding mode stabilizes an open and a closed intermediate structural state and provide structural insight into the transition required for catalysis. This results in a significant rearrangement of both the protein active site and the orientation of the alkynylpyrimidine ligand when compared to the observed orientation of nucleosidic inhibitors or substrates.


==About this Structure==
==About this Structure==
Line 13: Line 13:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Muchmore, S.W.]]
[[Category: Muchmore, S W.]]
[[Category: 5I5]]
[[Category: 5I5]]
[[Category: 5'-deoxy-5-iodotubercidin]]
[[Category: 5'-deoxy-5-iodotubercidin]]
[[Category: protein-ligand complex]]
[[Category: protein-ligand complex]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 17:35:00 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:49:35 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA